The Journal of Antibiotics banner image

Welcome to
The Journal of Antibiotics

An International Journal Devoted to Research on Bioactive Microbial Products


  • Cycloimidamicins, Novel natural lead compounds for translation inhibition in Pseudomonas aeruginosa

    Antimicrobial polyketides from Magellan Seamount-derived fungus Talaromyces scorteus AS-242

    When less is more: shortening the Lpp protein leads to increased vancomycin resistance in Escherichia coli

  • The October 2021 special issue of The Journal of Antibiotics “Approach toward molecular targeted therapy for cancer using microbial products” focuses on microbial secondary metabolites targeting molecules or signal transduction systems related to cancer development. We would like to thank Profs. Masaya Imoto and Manabu Kawada, the coordinators of this special issue.

  • The October 2020 special issue of The Journal of Antibiotics “Secondary Metabolites from Mushrooms” focuses on the compounds produced by mushrooms or cultured mycelia of mushrooms. We are extremely grateful to all the researchers for their diligence in contributing their work during the unprecedented time of the coronavirus pandemic. Coordinators: Profs. Timm Anke and Kazuro Shiomi.

  • The World Health Organization (WHO) publishes annual updates to new antibacterials in the pipeline. There is a call to submit the information on your lead traditional and non-traditional molecules. Building awareness about your antibacterial discovery program is of great value to you and the scientific community. The call is open until 17 April 2023. Please click here to submit your information.

The Journal of Antibiotics is a Transformative Journal; authors can publish using the traditional publishing route OR via immediate gold Open Access.

Our Open Access option complies with funder and institutional requirements.